# US 2022/0033623 A1 · Conjugates of hyaluronic acid and aminobisphosphonates and the therapeutic use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033623 A1
- Document ID: US20220033623A1
- Status: Published application
- Kind: A1
- Application number: 17/279,888
- Filed: 2019-10-11
- Published: 2022-02-03
- Earliest claimed: 2018-10-15
- Assignees: Fidia Farmaceutici S.P.A.
- Applicants: Fidia Farmaceutici S.P.A.
- Inventors: Stefano PLUDA; Mauro PAVAN; Carlo BARBERA
- Web page: https://patentgrep.com/patent/US20220033623A1

## CPC

- C08B 37/0072: {Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates}
- C08L 5/08: Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
- A61K 47/548: {Phosphates or phosphonates, e.g. bone-seeking (phospholipids A61K47/544)}
- A61K 47/55: the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- A61K 47/61: the organic macromolecular compound being a polysaccharide or a derivative thereof
- C08B: POLYSACCHARIDES; DERIVATIVES THEREOF (polysaccharides containing less than six saccharide radicals attached to each other by glycosidic linkages C07H; fermentation or enzyme-using processes C12P19/00; sugar industry C13; production of cellulose D21)
- C08L: COMPOSITIONS OF MACROMOLECULAR COMPOUNDS (compositions based on polymerisable monomers C08F, C08G; artificial filaments or fibres D01F; textile treating compositions D06)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention describes conjugates of hyaluronic acid (HA) and an amino-bisphosphonate (N-BP) of general formula (I): wherein L, m, n and x are as defined in claim 1, and the salts thereof Said conjugates and the pharmaceutical compositions thereof are useful in the intra-articular and/or locoregional treatment of osteoarthrosis and its repercussions at cartilage and subchondral level; in the treatment of post-menopausal or drug-induced osteoporosis; in the treatment of bone fragility due to trauma or disease; and in the intraosseous and/or locoregional treatment of disorders characterised by altered metabolic bone turnover, in particular Paget's disease. They are also useful to improve the osseointegration of prostheses.

## Claims

### Claim 1

A conjugate between hyaluronic acid and an amino-bisphosphonate, of formula (I)
wherein:
L is a spacer of formula —(CH2)m—, wherein m is an integer from 2 to 10; or L is a spacer of formula —(CH2CH2O)p—CH2CH2— wherein p is an integer from 1 to 4;
n is an integer from 2 to 5;
x is a number that represents the degree of substitution (DS) of hyaluronic acid with the amino-bisphosphonate in relation to the carboxylic groups of hyaluronic acid, ranging from 0.05 to 0.30 mol of amino-bisphosphonate/mol of hyaluronic acid:
the weight-average molecular weight of hyaluronic acid ranges from 30000 Da to 3×106 Da;
the phosphonic groups of the amino-bisphosphonic moiety and the carboxyl groups of hyaluronic acid that are not involved in the conjugation with the amino-bisphosphonate are, optionally, partially or completely salified with the cation of an alkali or alkaline-earth metal, with the ammonium cation or with a (C1-C4)tetraalkylammonium cation, preferably with a cation of an alkaline metal, more preferably with the Na+ cation.

### Claim 2 (depends on 1)

Conjugate according to claim 1, wherein m is an integer from 2 to 5.

### Claim 3 (depends on 1)

Conjugate according to claim 1, wherein p is 1.

### Claim 4 (depends on 1)

Conjugate according to claim 1, wherein n is 2, 3 or 5.

### Claim 5 (depends on 1)

Conjugate according to claim 1, wherein both m and n are 2.

### Claim 6 (depends on 1)

Conjugate according to claim 1, wherein the weight-average molecular weight of hyaluronic acid ranges from 1×105 Da to 1×106 Da, more preferably from 150000 Da to 800000 Da, and even more preferably from 170000 Da to 230000 Da or from 500000 Da to 730000 Da.

### Claim 7 (depends on 1)

Conjugate according to claim 1, wherein x ranges from 0.10 to 0.30 mol/mol, more preferably from 0.10 to 0.20 mol/mol.

### Claim 8 (depends on 1)

A conjugate of formula (I) as defined in claim 1 for use as a medicament.

### Claim 9 (depends on 1)

Pharmaceutical composition containing a conjugate of formula (I) as defined in claim 1, and at least one pharmaceutically acceptable excipient and/or carrier.

### Claim 10 (depends on 1)

A method of intra-articularly and/or locoregionally treating osteoarthrosis and its repercussions at cartilage and subchondral level; treating post-menopausal osteoporosis or osteoporosis induced by drugs; treating bone fragility due to traumas or diseases, intraosseously and/or locoregionally treating diseases characterised by altered metabolic bone turnover; and treating and filling of subchondral bone lesion, which comprises administering to a patient in need there of the conjugate according to claim 1.

### Claim 11 (depends on 1)

A method of improving osseointegration of prostheses, which comprises administering to a patient in need there of the conjugate according to claim 1.

### Claim 12 (depends on 1)

A viscosupplement comprising a conjugate of formula (I) as defined in claim 1, and at least one pharmaceutically acceptable excipient and/or carrier.

### Claim 13 (depends on 12)

A method of intra-articularly and/or locoregionally treating osteoarthrosis and its repercussions at cartilage and subchondral level; treating post-menopausal osteoporosis or osteoporosis induced by drugs, especially steroids; treating bone fragility due to traumas or diseases; and intraosseously and/or locoregionally treating diseases characterised by altered metabolic bone turnover, which comprises administering to a patient in need thereof the viscosupplement of claim 12.

### Claim 14 (depends on 10)

The method according to claim 10, wherein the osteoporosis is induced by steroids.

### Claim 15 (depends on 10)

The method according to claim 10, wherein the bone fragility is due to multiple myeloma and/or bone metastases.

### Claim 16 (depends on 10)

The method according to claim 10, wherein the altered metabolic turnover is Paget's disease.

### Claim 17 (depends on 10)

The method according to claim 10, wherein the subchondral bone lesions are bone marrow lessions.

### Claim 18 (depends on 13)

The method according to claim 13, wherein the osteoporosis is induced by steroids.

### Claim 19 (depends on 13)

The method according to claim 13, wherein the bone fragility is due to multiple myeloma and/or bone metastases.

### Claim 20 (depends on 13)

The method according to claim 13, wherein the altered metabolic turnover is Paget's disease.
